Profile data is unavailable for this security.
About the company
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
- Revenue in USD (TTM)75.21m
- Net income in USD-166.94m
- Incorporated2011
- Employees263.00
- LocationADC Therapeutics SABiopole, route de la Corniche 3BEPALINGES 1066SwitzerlandCHE
- Phone+41 216530200
- Websitehttps://adctherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adlai Nortye Ltd (ADR) | 0.00 | -42.59m | 459.33m | 123.00 | -- | 36.62 | -- | -- | -1.14 | -1.14 | 0.00 | 0.2147 | 0.00 | -- | -- | 0.00 | -47.40 | -- | -138.41 | -- | -- | -- | -- | -- | -- | -26.36 | 0.8491 | -- | -- | -- | 52.51 | -- | -- | -- |
| Prothena Corporation PLC | 9.68m | -244.09m | 466.71m | 163.00 | -- | 1.66 | -- | 48.19 | -4.53 | -4.53 | 0.1799 | 5.21 | 0.0222 | -- | -- | -- | -55.86 | -19.16 | -62.22 | -20.73 | -- | -- | -2,520.57 | -114.82 | -- | -- | -- | -- | -92.84 | 62.56 | -99.57 | -- | -- | -- |
| Kyverna Therapeutics Inc | 0.00 | -160.99m | 469.02m | 129.00 | -- | 2.37 | -- | -- | -3.72 | -3.72 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -61.17 | -- | -69.77 | -- | -- | -- | -- | -- | -- | -- | 0.0013 | -- | -- | -- | -111.17 | -- | -- | -- |
| Assembly Biosciences Inc | 37.19m | -38.55m | 471.98m | 73.00 | -- | 2.58 | -- | 12.69 | -4.81 | -4.81 | 4.33 | 11.55 | 0.2186 | -- | 81.56 | 509,465.80 | -22.66 | -41.01 | -31.44 | -47.70 | -- | -- | -103.65 | -319.31 | -- | -- | 0.00 | -- | 298.16 | 12.31 | 34.38 | -- | -55.21 | -- |
| Solid Biosciences Inc | 0.00 | -167.14m | 483.82m | 100.00 | -- | 2.22 | -- | -- | -2.49 | -2.49 | 0.00 | 2.80 | 0.00 | -- | -- | 0.00 | -68.82 | -47.92 | -78.37 | -53.98 | -- | -- | -- | -2,151.47 | -- | -- | 0.0013 | -- | -- | -- | -29.87 | -- | -31.66 | -- |
| Altimmune Inc | 20.00k | -83.92m | 486.31m | 59.00 | -- | 2.22 | -- | 24,315.64 | -1.07 | -1.07 | 0.0003 | 1.94 | 0.0001 | -- | 0.0314 | 338.98 | -45.82 | -42.36 | -48.64 | -45.46 | -- | -- | -419,575.00 | -3,193.88 | -- | -- | 0.0722 | -- | -95.31 | -67.83 | -7.48 | -- | -- | -- |
| Climb Bio Inc | 0.00 | -50.75m | 487.52m | 17.00 | -- | 2.75 | -- | -- | -0.7507 | -0.7507 | 0.00 | 2.60 | 0.00 | -- | -- | 0.00 | -25.09 | -39.53 | -25.62 | -41.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -110.42 | -- | -- | -- |
| 4D Molecular Therapeutics Inc | 120.00k | -209.18m | 492.74m | 227.00 | -- | 1.22 | -- | 4,106.13 | -3.74 | -3.74 | 0.0022 | 7.89 | 0.0002 | -- | -- | 528.63 | -40.70 | -32.02 | -43.51 | -33.96 | -- | -- | -174,314.20 | -895.24 | -- | -- | 0.00 | -- | -99.82 | -64.94 | -59.53 | -- | 3.40 | -- |
| ADC Therapeutics SA | 75.21m | -166.94m | 507.90m | 263.00 | -- | -- | -- | 6.75 | -1.51 | -1.51 | 0.6852 | -2.11 | 0.2355 | 0.3207 | 3.20 | 285,965.80 | -52.26 | -45.95 | -65.58 | -53.58 | 92.73 | -- | -221.97 | -263.96 | 4.34 | -2.91 | 2.10 | -- | 1.84 | 97.79 | 34.25 | -- | -16.59 | -- |
| Lyell Immunopharma Inc | 41.00k | -325.66m | 509.85m | 300.00 | -- | 1.41 | -- | 12,435.49 | -22.26 | -22.26 | 0.0027 | 17.06 | 0.00008 | -- | -- | 136.67 | -63.41 | -28.62 | -67.72 | -30.08 | -- | -- | -794,292.70 | -1,176.84 | -- | -- | 0.00 | -- | -53.08 | -37.83 | -46.18 | -- | 14.67 | -- |
| Lexeo Therapeutics Inc | 0.00 | -104.97m | 524.05m | 72.00 | -- | 3.26 | -- | -- | -2.70 | -2.70 | 0.00 | 2.20 | 0.00 | -- | -- | 0.00 | -66.08 | -- | -76.72 | -- | -- | -- | -- | -- | -- | -- | 0.0084 | -- | -- | -- | -48.11 | -- | -- | -- |
| Vanda Pharmaceuticals Inc. | 216.11m | -220.47m | 526.65m | 533.00 | -- | 1.61 | -- | 2.44 | -3.74 | -3.74 | 3.67 | 5.54 | 0.3774 | 7.29 | 4.25 | 405,450.30 | -38.51 | -6.49 | -48.99 | -7.64 | 93.96 | 92.12 | -102.02 | -17.46 | 2.38 | -- | 0.0224 | -- | 8.72 | -2.73 | -1,066.53 | -- | -11.08 | -- |
| Larimar Therapeutics Inc | 0.00 | -132.00m | 534.14m | 65.00 | -- | 3.27 | -- | -- | -1.93 | -1.93 | 0.00 | 1.62 | 0.00 | -- | -- | 0.00 | -64.96 | -45.05 | -76.53 | -50.22 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -118.15 | -- | -7.58 | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -223.12m | 543.93m | 202.00 | -- | 1.96 | -- | -- | -2.01 | -2.01 | 0.00 | 2.56 | 0.00 | -- | -- | 0.00 | -52.00 | -42.96 | -56.68 | -46.18 | -- | -- | -- | -- | -- | -- | 0.0713 | -- | -- | -- | 13.77 | -- | -56.75 | -- |
| Fulcrum Therapeutics Inc | 0.00 | -74.88m | 558.11m | 55.00 | -- | 1.60 | -- | -- | -1.18 | -1.18 | 0.00 | 5.24 | 0.00 | -- | -- | 0.00 | -23.89 | -30.35 | -24.84 | -32.48 | -- | -- | -- | -344.07 | -- | -- | 0.00 | -- | -100.00 | -- | -669.97 | -- | -25.21 | -- |
Data as of Mar 02 2026. Currency figures normalised to ADC Therapeutics SA's reporting currency: US Dollar USD
42.57%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Redmile Group LLCas of 31 Dec 2025 | 15.67m | 12.65% |
| Prosight Management LPas of 31 Dec 2025 | 8.48m | 6.84% |
| Nantahala Capital Management LLCas of 31 Dec 2025 | 5.48m | 4.42% |
| Point72 Asset Management LPas of 31 Dec 2025 | 5.01m | 4.05% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 4.85m | 3.92% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 3.72m | 3.01% |
| Eventide Asset Management LLCas of 31 Dec 2025 | 3.36m | 2.72% |
| OrbiMed Advisors LLCas of 31 Dec 2025 | 3.23m | 2.61% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2025 | 1.52m | 1.23% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 1.41m | 1.14% |
More ▼
Data from 31 Dec 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
